StockWatch
·

Theriva Biologics, Inc. Q1 FY26 Results

TOVXQ1 FY26 Results
Filing
MetricValue ($ M)
Revenue0.30
Total Income0.30
Expenditure2.43
PBT-2.04
Net Profit-2.04
OPM—
NPM—
EPS-0.05
View full financials

Theriva Biologics Reports Q1 2026 Financial Results

06 May 2026 · 6 May, 2:11 am

Summary

Theriva Biologics reported its financial results for the first quarter ended March 31, 2026. The company's cash and cash equivalents totaled $14.4 million as of March 31, 2026. The company aligned with the FDA on the Phase 3 trial design of VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC). The net loss attributable to common stockholders was $2.044 million for the quarter ended March 31, 2026. Management is focusing on regulatory interactions regarding a proposed pivotal clinical trial of VCN-01 in retinoblastoma.

Key Highlights

  1. 1

    Theriva Biologics aligned with the FDA on the Phase 3 trial design of VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC).

  2. 2

    Additional data from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients was presented at the AACR Annual Meeting.

  3. 3

    VCN-01 was administered to retinoblastoma patients under a compassionate use program to assess dosing feasibility and tolerability.

  4. 4

    Cash and cash equivalents totaled $14.4 million as of March 31, 2026, providing a cash runway into Q1 2027.

  5. 5

    General and administrative expenses increased by 43% to $2.1 million for the three months ended March 31, 2026.

  6. 6

    Research and development expenses decreased by 88% to $355,000 for the three months ended March 31, 2026.

  7. 7

    The company reported a net loss attributable to common stockholders of $2.044 million for the quarter ended March 31, 2026.

Management Comments

S

Steven A. Shallcross

“The first quarter of 2026 was marked by encouraging regulatory progress,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We were pleased to receive the minutes from our end-of-Phase 2 meeting with the FDA and align on the major elements of our proposed pivotal Phase 3 trial to evaluate VCN-01 with gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy in patients with metastatic PDAC. The FDA feedback was consistent with the positive scientific advice previously received from the EMA, with both agencies agreeing to repeated dosing ‘macrocycles’ of VCN-01 and SoC chemotherapy. Additional data analyses presented in a poster at the AACR Annual Meeting in April 2026 concluded that the additional data may reflect a potential immune-mediated mechanism of action for VCN-01 in metastatic PDAC. We believe that repeated macrocycle dosing of VCN-01 and chemotherapy may enhance this immune action, providing increased and more durable tumor responses and longer survival. As we finalize the pivotal Phase 3 study protocol, we plan to generate feasibility data for the intended Phase 3 macrocycle dosing regimen, by conducting a small study in metastatic PDAC patients administering more frequent VCN-01 doses for a longer period. This dosing feasibility study is expected to commence at a single site in Spain in the second half of this year. In parallel with our PDAC program, discussions are ongoing with clinicians and key opinion leaders to design a Phase 2/3 clinical trial protocol for the VCN-01 plus topotecan combination in retinoblastoma patients. We believe that intravitreal coadministration of VCN-01 with topotecan may provide a new treatment option for children with refractory retinoblastoma and vitreous seeds, which remains an unmet medical need in patients with this rare disease. In the first quarter of 2026, we made VCN-01 available to investigators for compassionate use in treating patients with retinoblastoma. We expect that outcomes from these compassionate use patients will provide valuable information on the feasibility and tolerability of this combination for use in a potential Phase 2/3 clinical trial. If a protocol is ultimately submitted to, and agreed by, the FDA, we expect the first patient to be enrolled in December 2026, with rolling Biologic Licensing Application (BLA) submissions expected to be made in 2029 (if successful), targeting potential approval of the BLA prior to September 30, 2029.”

Informational and educational content only. Not investment advice.